GSK contract, UK clearance for CTVQ, and ASX 200 inclusion
Filed with ASX · · 4 pages · English
Summary by 6ix AI
4DMedical Ltd. has announced a contract with GlaxoSmithKline to provide lung imaging analytics for drug development, marking a significant strategic engagement in the pharmaceutical sector. The company has received UKCA certification for its CT:VQ™ technology, expanding its market presence in Europe and enhancing its capabilities in the UK diagnostic imaging market. The announcement highlights several regulatory and corporate milestones that validate the demand for 4DMedical's advanced imaging analytics platform.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from 4DMedical
- Insignia Financial to be removed from the S&P/ASX 200 Index
- 4DMedical receives CE Mark for CT: VQ™, enabling commercial launch across the European Union
- CE Mark for CTVQ and $83M placement to fund EU expansion
- CTVQ deployed at Mayo Clinic
- Update - S&P DJI March 2026 Rebalance of the All Ordinaries
Later from 4DMedical
- Major publication validates CTVQ for lung surgery
- CTVQ enters US Outpatient Market via SimonMed 170 sites
- 4DMedical creates EU platform via contextflow acquisition
- 4DMedical targets US$2.5B PE market entry for CTVQ
- 4DMedical receives TGA approval for CTVQ in Australia
Follow 4DMedical into a list and get an email when it puts out news.
Follow 4DMedical